<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679454</url>
  </required_header>
  <id_info>
    <org_study_id>AIRC IG-23118</org_study_id>
    <nct_id>NCT04679454</nct_id>
  </id_info>
  <brief_title>Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer</brief_title>
  <official_title>Phase I/II Clinical Trial on Single Fraction Ablative Preoperative Radiation Treatment for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, single-arm and open-label single-centre clinical trial with the aim to&#xD;
      test the feasibility, safety and the efficacy, in terms of complete pathological response, of&#xD;
      preoperative ablative radiotherapy in single fraction for selected breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research plan is conceived in two sections, as follows. (i)The technical study handles&#xD;
      the set-up, motion and dosimetric issues of the radioablation technique using CyberKnife&#xD;
      system.&#xD;
&#xD;
      (ii)The clinical section is organized in two studies: a phase I dose escalation study to&#xD;
      identify the maximum tolerated dose (MTD) delivering 18 Gy, 21 Gy and 24 Gy in single&#xD;
      fraction and a phase II study to evaluate the rate of pathological complete response (pCR)&#xD;
      when a dose level is chosen according to the results of the previous phase I study.&#xD;
&#xD;
      Study population includes patients affected by cT1-T2 (up to 2.5 cm) cN0, adenocarcinoma of&#xD;
      the breast, diagnosed with conventional workup. Surgical tumor removal will be scheduled&#xD;
      after 4-8 weeks after radioablation. Whole breast radiation therapy without boost will be&#xD;
      performed after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2021</start_date>
  <completion_date type="Anticipated">March 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Identify the maximum tolerated dose (MTD)</measure>
    <time_frame>time frame:2 weeks</time_frame>
    <description>Dose escalation is designed as a 3+3 rule-based study. Acute skin/soft tissue toxicity, measured according to NCI CTCAE v. 4.03. Any Grade 3-4 toxicity related to radioablation is considered dose limiting (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Evaluate efficacy measured in terms of pCR rate</measure>
    <time_frame>time frame:8 weeks</time_frame>
    <description>Rate of pCR after radioablative treatment, according to Modified Residual Cancer Burden (RCB) index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic toxicity</measure>
    <time_frame>time frame: 6 months - 3 years</time_frame>
    <description>Chronic skin/soft tissue, bone, lung and heart toxicities incidence measured according to NCI CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcomes</measure>
    <time_frame>time frame: 1 - 3 years</time_frame>
    <description>Measured according to the 4 points scale (poor, fair, good, excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post surgery complications</measure>
    <time_frame>time frame: within 30 days of surgery</time_frame>
    <description>Reporting of any post surgery complication (rate of infection, seroma, hematoma, necrosis, delayed wound healing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>time frame: 1- 3 years</time_frame>
    <description>establish the rate of disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local relapse</measure>
    <time_frame>time frame: 1 - 3 years</time_frame>
    <description>establish the rate of local relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time frame: 3 years</time_frame>
    <description>establish the rate of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer specific survival</measure>
    <time_frame>time frame: 3 years</time_frame>
    <description>establish the rate of breast cancer specific survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Preoperative Radiation Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Phase I</intervention_name>
    <description>To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.</description>
    <arm_group_label>Preoperative Radiation Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Phase II</intervention_name>
    <description>The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.</description>
    <arm_group_label>Preoperative Radiation Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven unifocal adenocarcinoma&#xD;
&#xD;
          -  T1-T2&#xD;
&#xD;
          -  Tumor size up to 2.5 cm&#xD;
&#xD;
          -  cN0&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Good general condition (ECOG 0-2)&#xD;
&#xD;
          -  Planned BCS&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor close to skin or chest wall&#xD;
&#xD;
          -  Pure non-invasive tumor&#xD;
&#xD;
          -  Prior RT to the chest&#xD;
&#xD;
          -  Neoadjuvant chemotherapy&#xD;
&#xD;
          -  Collagenopathies&#xD;
&#xD;
          -  Coagulation or autoimmunitary disorders&#xD;
&#xD;
          -  Previous malignancies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Cristina Leonardi, MD</last_name>
    <phone>+39 02 57489037</phone>
    <email>cristina.leonardi@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Morra, MD</last_name>
    <phone>+39 02 57489037</phone>
    <email>anna.morra@ieo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IEO, European Institute of Oncology IRCCS</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cristina Leonardi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>European Institute of Oncology</investigator_affiliation>
    <investigator_full_name>Cristina Leonardi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>preoperative radiotherapy</keyword>
  <keyword>radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

